Skip to main content

Table 3 Clinical baseline characteristics by treatment groups

From: Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis

Study

Ceftaroline group

Control group

Ceftaroline group

Control group

Ceftaroline group

Control group

Ceftaroline group

Control group

Ceftaroline group

Control group

 

PSI risk class III, n (%)

PSI risk class IV, n (%)

Severe CAPa, n (%)

Multilobar infiltrate, n (%)

Pleural effusion, n (%)

Jandourek et al.., 2014 [9]

5 (21.7)

5 (22.7)

18 (78.3)

15 (68.2)

5 (21.7)

5 (22.7)

5 (21.7)

5 (22.7)

File et al........, 2011 [10]

190 (65.3)

182 (60.7)

101 (34.7)

118 (39.3)

82 (28.2)

89 (29.7)

Low et al...., 2011 [11]

170 (58.8)

171 (62.6)

119 (41.2)

102 (37.4)

99 (34.3)

80 (29.3)

Shorr et al.........., 2013 [12]

34 (49.3)

37 (52.9)

35 (50.7)

33 (47.1)

22 (31.9)

32 (45.7)

18 (26.1)

21 (30.0)

15 (21.7)

13 (18.6)

File et al, 2010 [13]

360 (62.1)

353 (61.6)

220 (37.9)

220 (38.4)

Zhong et al.., 2015 [14]

255 (67.0)

265(69.4)

126 (33.1)

117 (30.6)

Arshad et al, 2016 [15]

Eckburg et al, 2012 [22]

84 (54.5)

82 (52.9)

61 (39.6)

61 (39.4)

 

Structural lung diseaseb, n (%)

Prior pneumonia, n (%)

Asthma, n (%)

Prior antimicrobial therapy, n (%)

Bacteremia, n (%)

Jandourek et al, 2014 [9]

23 (100.0)

22 (100.0)

File et al, 2011 [10]

64 (22.0)

60 (20.0)

61 (21.0)

51 (17.0)

25 (8.6)

25 (8.3)

137 (47.1)

143 (47.7)

8 (2.7)

9 (3.0)

Low et al, 2011 [11]

96 (33.2)

87 (31.9)

62 (21.5)

41 (15.0)

24 (8.3)

13 (4.8)

100 (34.6)

117 (42.9)

15 (5.2)

11 (4.0)

Shorr et al, 2013 [12]

26 (37.7)

32 (45.7)

19 (27.5)

13 (18.6)

File et al, 2010 [13]

160 (27.6)

147 (25.7)

123 (21.2)

92 (16.1)

49 (8.4)

38 (6.6)

23 (4.0)

20 (3.5)

Zhong et al, 2015 [14]

120 (31.5)c

121 (31.7)c

21 (5.5)

22 (5.8)

80 (21.0)

85 (22.3)

3 (0.8)

5 (1.3)

Arshad et al, 2016 [15]

8 (20.0)

31 (28.4)

4 (11.8)

24 (23.3)

Eckburg et al, 2012 [22]

43 (27.9)

41 (26.5)

57 (37.0)

68 (43.9)

23 (14.9)

21 (13.5)

 

Diabetes mellitus, n (%)

Jandourek et al, 2014

        

File et al, 2011

        

Low et al, 2011

        

Shorr et al, 2013

        

File et al, 2010

        

Zhong et al, 2015

62 (16.3)

62 (16.3)

        

Arshad et al., 2016

10 (25.0)

20 (18.4)

        

Eckburg et al..., 2012

        
  1. aModified ATS severe CAP criteria include the presence of three or more of the following at baseline: respiratory rate ≥ 30 breaths/min; O2,90% or PaO2,60 mmHg; multilobar infiltrates; confusion/disorientation; blood urea nitrogen level ≥ 20 mg/dL; leucopenia (WBC count,4000 cells/mm3); thrombocytopenia (platelet count,100,000 cells/mm3); hypothermia (core temperature,368C); systolic blood pressure,90 mmHg; or diastolic blood pressure ≤ 60 mmHg. (Niederman MS, Mandell LA, Anzuetto A et al............ Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730–54)
  2. bDefined as any chronic parenchymal or airway disease [e.g. chronic obstructive pulmonary disease (emphysema, chronic bronchitis), bronchiectasis, or interstitial fibrosis]
  3. conly COPD and chronic bronchitis